Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

The number of people seeking medical care for three key illnesses — COVID-19, flu and respiratory syncytial virus, or RSV — ...

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

Kennedy Jr. made another vaccine-related change at the agency late last week, repealing a federal policy that financially ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

The Health and Human Services secretary said he is reviewing whether to remove the medical experts on the U.S. Preventive Services Task Force who advise on cancer screenings, HIV prevention drugs, and ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...

Pfizer raised its full-year profit forecast on Tuesday after topping Wall Street expectations for second-quarter results as ...

The trade war between China and the US is entering the next round and reaching a new peak. The Middle Kingdom is restricting ...